Boston Scientific announces results for third quarter 2026

Boston Scientific’s Q3 profit fell despite modest sales growth and new product clearances.

What the company is saying

Boston Scientific reports Q3 2026 net sales of $5.138 billion, up 1.5% year-over-year, emphasizing resilience in the face of a cybersecurity incident and highlighting operational recovery. The company frames its narrative around steady sales growth, new product launches, and regulatory milestones, while acknowledging a challenging year. CEO Mike Mahoney, named as chairman and chief executive officer, credits global teams for restoring operations and expresses confidence in the long-term strategy, citing a differentiated portfolio and innovation pipeline. The announcement details FDA 510(k) clearances for new StoneSmart Solutions and SEISMIQ catheter sizes, the start of the Elite AF clinical trial, and a strategic collaboration with Heartflow, Inc. (NASDAQ:HTFL) to advance AI-powered PCI planning. The company also notes the American Medical Association’s assignment of Category I CPT codes for two device classes, effective January 2028. Guidance for full-year 2026 is for 4.25% reported and 3.75% organic net sales growth, with adjusted EPS of $3.16 to $3.18, but Q4 2026 is forecast to see a net sales decline of 1–3% and adjusted EPS of $0.77 to $0.79.

What the data suggests

The numbers show a mixed quarter: net sales rose 1.5% to $5.138 billion, but GAAP net income dropped to $582 million ($0.40 per share) from $755 million ($0.51 per share) a year earlier. Adjusted EPS also fell to $0.73 from $0.75. Segment performance was uneven, with Neuromodulation up 13.1% and Cardiovascular up 1.9%, but Endoscopy and Urology declined by 0.8% and 3.2%, respectively. Regionally, Latin America and Canada grew 16.0%, EMEA rose 4.4%, but APAC declined 0.6% and the U.S. grew only 0.5%. The company’s guidance for Q4 2026 points to a sales decline of 1–3% and flat to slightly lower adjusted EPS, indicating near-term headwinds. Management attributes operational challenges in part to a cybersecurity incident but claims successful restoration of operations. The company continues to invest in product development and regulatory expansion, as seen in new FDA clearances and clinical trial initiations, but these have not yet translated into profit growth.

Analysis

The announcement is balanced and factual, with the majority of claims supported by realised financial and operational data for Q3 2026. The company discloses both GAAP and adjusted profitability metrics, as well as detailed segment and regional sales, which show modest growth in some areas but declines in others. Forward-looking statements are limited to full-year and Q4 2026 guidance, which actually forecast a decline in sales for the next quarter and only modest growth for the year. There is no evidence of exaggerated language or narrative inflation; the only promotional phrase is the CEO's confidence in the long-term strategy, which is standard and not excessive. The strategic collaboration with Heartflow is disclosed factually, with no outsized claims about its immediate impact. The data supports a weak_positive signal due to comprehensive disclosure and operational progress, but the deterioration in profitability and muted guidance prevent a stronger rating.

Risk flags

• ●Profitability is deteriorating: GAAP net income fell from $755 million to $582 million year-over-year, and adjusted EPS declined, signaling margin pressure despite higher sales.
• ●Q4 2026 guidance is negative: The company expects net sales to decline by 1–3% and adjusted EPS to remain flat or fall, indicating ongoing operational or market challenges.
• ●Segment and regional volatility: Endoscopy and Urology segments posted sales declines, and APAC sales fell, suggesting uneven demand and potential competitive or macroeconomic risks.
• ●Execution risk on innovation: While multiple products received FDA clearance and new trials began, these initiatives require successful commercialization and adoption to impact future earnings.
• ●Long-dated reimbursement milestones: The new CPT codes for certain devices are effective only in January 2028, delaying any financial benefit from these regulatory wins.

Bottom line

Boston Scientific delivered modest sales growth in Q3 2026, but profitability declined, and guidance points to further pressure in the near term. The company is advancing its product pipeline with new FDA clearances, a major clinical trial, and a strategic AI collaboration, but these initiatives have yet to offset margin headwinds or drive earnings growth. Regional and segment results are mixed, with notable strength in Neuromodulation and Latin America/Canada, but weakness in Endoscopy, Urology, and APAC. The CEO’s confidence is not yet matched by improving financials, and investors should focus on whether new products and collaborations can reverse the earnings trend. The most important takeaway is that while operational recovery and innovation are underway, near-term financial performance remains under pressure and improvement will depend on execution and market uptake of new technologies.

Announcement summary

(NYSE:BSX) Boston Scientific Corporation reported net sales of $5.138 billion for the third quarter of 2026, representing a 1.5 percent increase on a reported, operational, and organic basis compared to the prior year period. GAAP net income attributable to Boston Scientific common stockholders was $582 million, or $0.40 per share, compared to $755 million or $0.51 per share a year ago. Adjusted EPS for the period was $0.73, down from $0.75 in the prior year period. MedSurg segment net sales grew by 0.6 percent reported, 0.7 percent operational and organic, while Cardiovascular segment net sales increased by 1.9 percent reported, operational, and organic. Endoscopy net sales were $741 million, down from $747 million, a decrease of (0.8) percent reported and (0.6) percent organic. Urology net sales were $661 million, down from $682 million, a decrease of (3.2) percent reported and (3.1) percent organic. Neuromodulation net sales were $331 million, up from $293 million, an increase of 13.1 percent reported and 13.0 percent organic. By region, United States net sales were $3,309 million, up from $3,294 million, a 0.5 percent increase. EMEA net sales were $829 million, up from $793 million, a 4.4 percent reported and 6.1 percent operational increase. APAC net sales were $797 million, down from $802 million, a (0.6) percent reported and (1.1) percent operational decrease. Latin America and Canada net sales were $203 million, up from $175 million, a 16.0 percent reported and 10.5 percent operational increase. The company commenced enrollment in the Elite AF clinical trial to evaluate the WATCHMAN Elite™ Left Atrial Appendage Closure Device. Boston Scientific received U.S. FDA 510(k) clearance for two StoneSmart™ Solutions technologies: the Navigator™ Flex Ureteral Access Sheath Set and the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope with temperature sensing. The company also received FDA 510(k) clearance for an expanded size offering of the SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter. The American Medical Association assigned Category I CPT® codes for renal denervation devices, such as the investigational TIVUS™ Renal Denervation System, and implantable tibial nerve stimulation devices, including the eCoin® ITNS System, effective January 2028. Boston Scientific entered into a strategic collaboration with Heartflow, Inc. (Nasdaq: HTFL) to advance AI-powered CT-guided planning for PCI procedures and explore integration of Heartflow's PCI Navigator and the AVVIGO™+ Multi-Modality Guidance System. For the full year 2026, the company estimates net sales growth of approximately 4.25 percent reported and 3.75 percent organic, and adjusted EPS of $3.16 to $3.18. For the fourth quarter of 2026, net sales are estimated to decline by approximately (3.0) to (1.0) percent reported and organic, with adjusted EPS guidance of $0.77 to $0.79. Boston Scientific management will discuss these results on a conference call at 8:00 a.m. ET, with a webcast available on the company's website.

Disagree with this article?